NEW YORK (GenomeWeb) – B. Braun China and CeGaT of Germany have partnered to bring clinical genetic testing services to China.
As part of the collaboration, B. Braun China founded a subsidiary, called B. Braun Precision Medicine Technology (BBPM), that opened in Shanghai in May.
BBPM will provide clinical genetic testing and counseling services in the areas of hereditary disease and oncology. In addition, it will offer health management consulting to consumers and genomic testing to medical centers and clinicians. B. Braun said the founding of BBPM represents a milestone for the company, marking its entry into the personalized medicine market in China.
CeGaT said it plans to offer its full menu of diagnostics products in China through the collaboration, starting with its recently launched disease prevention panel, its epilepsy panel, neuromuscular disease panel, somatic and germline tumor panel, and trio exomes. Testing will be conducted at CeGaT's CLIA-certified and CAP-accredited lab in Germany as well as in China.
B. Braun is a privately owned German healthcare and medical device company with more than 60,000 employees globally and more than €6.5 billion ($7.6 billion) in annual revenues. It holds a 30 percent stake in CeGaT. In 2014, the companies founded a US subsidiary, called B. Braun CeGaT.